文献速递神经肿瘤

溶瘤腺病毒Delta-24-RGD联合ONC201在儿童高级别胶质瘤与弥漫性中线胶质瘤模型中诱导强效抗肿瘤反应

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.
PubMed 文献 · Neuro Oncol · 2024-01-01

本研究在儿童高级别胶质瘤(pHGG)与弥漫性中线胶质瘤(DMG)细胞系及小鼠模型中评估Delta-24-RGD与ONC201联合方案。体外联合不影响病毒复制能力,细胞毒性呈协同或相加效应;机制上联合增加核DNA损伤并维持各自所致的代谢扰动与线粒体损伤。联合治疗延长荷瘤小鼠总生存,不依赖H3突变状态与肿瘤位置,并将小鼠DMG肿瘤微环境重塑为促炎表型。

要点

  • Delta-24-RGD联合ONC201在pHGG与DMG体外模型中不影响病毒复制能力,细胞毒性为协同或相加。
  • 联合治疗增加核DNA损伤,并维持单药所致的代谢扰动与线粒体损伤。
  • 联合治疗延长荷瘤小鼠总生存,不依赖H3突变状态与肿瘤位置,并重塑DMG微环境为促炎表型。

核心结论

  • 在体外与体内模型中,Delta-24-RGD联合ONC201较各自单药提高疗效,机制为增强核DNA损伤并进而改善对单药的抗肿瘤(免疫)反应。

研究设计与样本

  • 研究采用人源与鼠源pHGG及DMG细胞系进行体外实验,并用两种疾病的小鼠模型评估联合方案体内疗效。
  • 通过免疫印迹与复制实验评估功能性病毒产生,通过RNAseq、海马应激测试、线粒体DNA含量与γH2A.X免疫荧光进行机制研究。
  • 采用流式细胞术、RNAseq与多重免疫荧光染色评估肿瘤免疫微环境。

主要发现

  • 联合治疗在人pHGG与DMG体外模型中不影响病毒复制能力。
  • 细胞毒性分析显示联合治疗为协同或相加效应。
  • 联合治疗增加核DNA损伤,并维持各单药所致的代谢扰动与线粒体损伤。
  • 联合治疗延长植入人源与鼠源pHGG及DMG细胞小鼠的总生存,不依赖H3突变状态与位置。
  • 在小鼠DMG模型中,联合治疗将肿瘤微环境重塑为促炎表型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, the combination of both agents has not been evaluated. METHODS: The production of functional viruses was assessed by immunoblotting and replication assays. The antitumor effect was evaluated in a panel of human and murine pHGG and DMG cell lines. RNAseq, the seahorse stress test, mitochondrial DNA content, and γH2A.X immunofluorescence were used to perform mechanistic studies. Mouse models of both diseases were used to assess the efficacy of the combination in vivo. The tumor immune microenvironment was evaluated using flow cytometry, RNAseq, and multiplexed immunofluorescence staining. RESULTS: The Delta-24-RGD/ONC201 combination did not affect the virus replication capability in human pHGG and DMG models in vitro. Cytotoxicity analysis showed that the combination treatment was either synergistic or additive. Mechanistically, the combination treatment increased nuclear DNA damage and maintained the metabolic perturbation and mitochondrial damage caused by each agent alone. Delta-24-RGD/ONC201 cotreatment extended the overall survival of mice implanted with human and murine pHGG and DMG cells, independent of H3 mutation status and location. Finally, combination treatment in murine DMG models revealed a reshaping of the tumor microenvironment to a proinflammatory phenotype. CONCLUSIONS: The Delta-24-RGD/ONC201 combination improved the efficacy compared to each agent alone in in vitro and in vivo models by potentiating nuclear DNA damage and in turn improving the antitumor (immune) response to each agent alone.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. de la Nava D, Ausejo-Mauleon I, Laspidea V, et al. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol. 2024. PMID: 38554031. doi:10.1093/neuonc/noae066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。